Last reviewed · How we verify
Ryanodex and Standard of Care
Ryanodex and Standard of Care is a Ryanodine receptor antagonist Small molecule drug developed by Eagle Pharmaceuticals, Inc.. It is currently in Phase 3 development for Malignant hyperthermia crisis (acute treatment), Malignant hyperthermia susceptibility (prophylaxis). Also known as: Ryanodex and SOC.
Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor.
Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor. Used for Malignant hyperthermia crisis (acute treatment), Malignant hyperthermia susceptibility (prophylaxis).
At a glance
| Generic name | Ryanodex and Standard of Care |
|---|---|
| Also known as | Ryanodex and SOC |
| Sponsor | Eagle Pharmaceuticals, Inc. |
| Drug class | Ryanodine receptor antagonist |
| Target | Ryanodine receptor (RyR1) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology / Critical Care |
| Phase | Phase 3 |
Mechanism of action
Dantrolene acts as a ryanodine receptor antagonist, preventing uncontrolled calcium efflux from intracellular stores in skeletal muscle. This mechanism is particularly effective in treating malignant hyperthermia, a pharmacogenetic crisis triggered by certain anesthetics and depolarizing muscle relaxants. By reducing intracellular calcium availability, dantrolene prevents the hypermetabolic cascade and muscle rigidity characteristic of malignant hyperthermia.
Approved indications
- Malignant hyperthermia crisis (acute treatment)
- Malignant hyperthermia susceptibility (prophylaxis)
Common side effects
- Muscle weakness
- Phlebitis at injection site
- Drowsiness
- Dizziness
- Nausea
Key clinical trials
- Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS) (PHASE2)
- Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS (PHASE3)
- Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ryanodex and Standard of Care CI brief — competitive landscape report
- Ryanodex and Standard of Care updates RSS · CI watch RSS
- Eagle Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Ryanodex and Standard of Care
What is Ryanodex and Standard of Care?
How does Ryanodex and Standard of Care work?
What is Ryanodex and Standard of Care used for?
Who makes Ryanodex and Standard of Care?
Is Ryanodex and Standard of Care also known as anything else?
What drug class is Ryanodex and Standard of Care in?
What development phase is Ryanodex and Standard of Care in?
What are the side effects of Ryanodex and Standard of Care?
What does Ryanodex and Standard of Care target?
Related
- Drug class: All Ryanodine receptor antagonist drugs
- Target: All drugs targeting Ryanodine receptor (RyR1)
- Manufacturer: Eagle Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Anesthesiology / Critical Care
- Indication: Drugs for Malignant hyperthermia crisis (acute treatment)
- Indication: Drugs for Malignant hyperthermia susceptibility (prophylaxis)
- Also known as: Ryanodex and SOC
- Compare: Ryanodex and Standard of Care vs similar drugs
- Pricing: Ryanodex and Standard of Care cost, discount & access